Embattled Salix hires bankers to weigh a potential sale

Salix Pharmaceuticals ($SLXP) has taken a step toward a potential sale. Haunted by an inventory snafu and a C-suite shakeup, the company was already facing investor pressure to look for bidders once its supply issues were resolved. Now, Salix has tapped Crestview Partners to "explore options" as it hunts for a new CEO. No decision is expected until after that person comes on board, however. Report

Suggested Articles

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.